Wietske Kievit1, Noortje van Herwaarden2, Frank Hj van den Hoogen3, Ronald F van Vollenhoven4, Johannes Wj Bijlsma5, Bart Jf van den Bemt6, Aatke van der Maas2, Alfons A den Broeder2. 1. Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands. 2. Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands. 3. Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands Department of Rheumatology, Radboud university medical center, Nijmegen, The Netherlands. 4. ClinTRID, Karolinska Institute, Stockholm, Sweden. 5. Department of Rheumatology & Immunology, Utrecht University Medical Centre, Utrecht, The Netherlands. 6. Department of Pharmacy, Sint Maartenskliniek, Nijmegen, The Netherlands Department of Pharmacy, Radboud university medical center, Nijmegen, The Netherlands.
Abstract
BACKGROUND: A disease activity-guided dose optimisation strategy of adalimumab or etanercept (TNFi (tumour necrosis factor inhibitors)) has shown to be non-inferior in maintaining disease control in patients with rheumatoid arthritis (RA) compared with usual care. However, the cost-effectiveness of this strategy is still unknown. METHOD: This is a preplanned cost-effectiveness analysis of the Dose REduction Strategy of Subcutaneous TNF inhibitors (DRESS) study, a randomised controlled, open-label, non-inferiority trial performed in two Dutch rheumatology outpatient clinics. Patients with low disease activity using TNF inhibitors were included. Total healthcare costs were measured and quality adjusted life years (QALY) were based on EQ5D utility scores. Decremental cost-effectiveness analyses were performed using bootstrap analyses; incremental net monetary benefit (iNMB) was used to express cost-effectiveness. RESULTS:180 patients were included, and 121 were allocated to the dose optimisation strategy and 59 to control. The dose optimisation strategy resulted in a mean cost saving of -€12 280 (95 percentile -€10 502; -€14 104) per patient per 18 months. There is an 84% chance that the dose optimisation strategy results in a QALY loss with a mean QALY loss of -0.02 (-0.07 to 0.02). The decremental cost-effectiveness ratio (DCER) was €390 493 (€5 085 184; dominant) of savings per QALY lost. The mean iNMB was €10 467 (€6553-€14 037). Sensitivity analyses using 30% and 50% lower prices for TNFi remained cost-effective. CONCLUSIONS: Disease activity-guided dose optimisation of TNFi results in considerable cost savings while no relevant loss of quality of life was observed. When the minimal QALY loss is compensated with the upper limit of what society is willing to pay or accept in the Netherlands, the net savings are still high. TRIAL REGISTRATION NUMBER: NTR3216; Post-results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
RCT Entities:
BACKGROUND: A disease activity-guided dose optimisation strategy of adalimumab or etanercept (TNFi (tumour necrosis factor inhibitors)) has shown to be non-inferior in maintaining disease control in patients with rheumatoid arthritis (RA) compared with usual care. However, the cost-effectiveness of this strategy is still unknown. METHOD: This is a preplanned cost-effectiveness analysis of the Dose REduction Strategy of Subcutaneous TNF inhibitors (DRESS) study, a randomised controlled, open-label, non-inferiority trial performed in two Dutch rheumatology outpatient clinics. Patients with low disease activity using TNF inhibitors were included. Total healthcare costs were measured and quality adjusted life years (QALY) were based on EQ5D utility scores. Decremental cost-effectiveness analyses were performed using bootstrap analyses; incremental net monetary benefit (iNMB) was used to express cost-effectiveness. RESULTS: 180 patients were included, and 121 were allocated to the dose optimisation strategy and 59 to control. The dose optimisation strategy resulted in a mean cost saving of -€12 280 (95 percentile -€10 502; -€14 104) per patient per 18 months. There is an 84% chance that the dose optimisation strategy results in a QALY loss with a mean QALY loss of -0.02 (-0.07 to 0.02). The decremental cost-effectiveness ratio (DCER) was €390 493 (€5 085 184; dominant) of savings per QALY lost. The mean iNMB was €10 467 (€6553-€14 037). Sensitivity analyses using 30% and 50% lower prices for TNFi remained cost-effective. CONCLUSIONS: Disease activity-guided dose optimisation of TNFi results in considerable cost savings while no relevant loss of quality of life was observed. When the minimal QALY loss is compensated with the upper limit of what society is willing to pay or accept in the Netherlands, the net savings are still high. TRIAL REGISTRATION NUMBER: NTR3216; Post-results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Manuel J Cárdenas; Soraya de la Fuente; María C Castro-Villegas; Montserrat Romero-Gómez; Desiré Ruiz-Vílchez; Jerusalem Calvo-Gutiérrez; Alejandro Escudero-Contreras; José R Del Prado; Eduardo Collantes-Estévez; Pilar Font Journal: Rheumatol Int Date: 2017-06-09 Impact factor: 2.631
Authors: Lise M Verhoef; Bart Jf van den Bemt; Aatke van der Maas; Johanna E Vriezekolk; Marlies E Hulscher; Frank Hj van den Hoogen; Wilco Ch Jacobs; Noortje van Herwaarden; Alfons A den Broeder Journal: Cochrane Database Syst Rev Date: 2019-05-24
Authors: Stéphanie Dierckx; Tatiana Sokolova; Bernard R Lauwerys; Aleksandra Avramovska; Laurent Meric de Bellefon; Adrien Nzeusseu Toukap; Maria Stoenoiu; Frédéric A Houssiau; Patrick Durez Journal: Arthritis Res Ther Date: 2020-04-28 Impact factor: 5.156
Authors: Selma Atalay; Juul M P A van den Reek; Marisol E Otero; Marcellus D Njoo; Johannes M Mommers; Paul M Ossenkoppele; Marjolein I Koetsier; Maartje M Berends; Peter C M van de Kerkhof; Hans M M Groenewoud; Alfons A den Broeder; Elke M G J de Jong; Wietske Kievit Journal: Acta Derm Venereol Date: 2020-12-01 Impact factor: 3.875
Authors: Evo Alemao; Maiwenn J Al; Annelies A Boonen; Matthew D Stevenson; Suzanne M M Verstappen; Kaleb Michaud; Michael E Weinblatt; Maureen P M H Rutten-van Mölken Journal: PLoS One Date: 2018-10-05 Impact factor: 3.240